Five things for pharma marketers to know: Friday, February 10, 2016

Share this content:

1. Lobbying group PhRMA filed a citizen petition asking the FDA to overhaul its new draft guidance, saying it contains unconstitutional policy changes to off-label marketing rules. The FDA in January had released new draft guidance addressing questions about how drugmakers can share truthful and non-misleading information outside of a drug's approved label. (Law360)

2. The FDA approved Marathon Pharmaceuticals' Duchenne muscular dystrophy drug, Emflaza, which is an older steroid drug that is inexpensive and available outside the U.S. Marathon priced the drug at $89,000 a year and received a rare pediatric-disease priority review voucher. (Endpts)

3. President Trump's pick for Secretary of Health and Human Services, Tom Price, was confirmed by the Senate by a vote of 52 to 47. Price opposed the Affordable Care Act. (WaPo)

4. Academic researchers, writing in Cell, said that cancer medicines should not cost more than $100,000 a year. “We need to be thinking about getting prices down toward a half or a third of that, ideally even less,” one of the paper's authors wrote. (Reuters)

5. Reckitt Benckiser agreed to buy Mead Johnson in a deal worth $16.6 billion. Reckitt CEO, Rakesh Kapoor, said the deal is a watershed moment for the company, citing increasing rates of women entering the workforce as one reason to enter the infant nutrition market. (Bloomberg)

Share this content:
Scroll down to see the next article